GlassScriptPhysician profile
Elshaday Teferi
NPI 1689215527
$10,997.40
in general payments reported to CMS, 2019-2025
29 companies · $3,294 in 2025
The $3,294 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $72.92 · 2022: $616 · 2023: $3,661 · 2024: $3,353 · 2025: $3,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,308.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $1,132.29 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,048.36 | 2022-2025 | Caplyta |
| Abbvie INC. | $948.91 | 2022-2025 | |
| Axsome Therapeutics, INC. | $899.15 | 2022-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $836.92 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $798.62 | 2022-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $741.50 | 2023-2025 | Austedo Xr, Uzedy, Austedo |
| Bausch Health US, LLC | $683.34 | 2022-2025 | Aplenzin, Wellbutrin |
| Neos Therapeutics, LP | $616.17 | 2023-2025 | Adzenys Xr-Odt |
| Vanda Pharmaceuticals INC. | $602.75 | 2022-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $593.48 | 2022-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Corium, LLC | $467.89 | 2023-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $274.21 | 2023-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Almatica Pharma LLC | $211.46 | 2022-2025 | Loreev Xr |
| E.R. Squibb & Sons, L.L.C. | $210.34 | 2024-2025 | Cobenfy |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $178.99 | 2023-2024 | Jornay Pm |
| Tris Pharma INC | $152.87 | 2023-2024 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $105.18 | 2023-2024 | Quviviq |
| Supernus Pharmaceuticals, INC. | $97.23 | 2024-2025 | Qelbree |
| Merck Sharp & Dohme LLC | $63.08 | 2023 | Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $61.13 | 2022-2025 | Trintellix |
| Collegium Pharmaceutical, INC. | $58.64 | 2025 | Jornay Pm |
| Pfizer INC. | $55.74 | 2021 | |
| Noven Therapeutics, LLC | $49.84 | 2024 | Xelstrym |
| Avanir Pharmaceuticals, INC. | $30.77 | 2022 | |
| Lifescan, INC. | $22.88 | 2022 | |
| Indivior INC. | $22.50 | 2024 | Perseris |
| Gilead Sciences, INC. | $17.18 | 2021 | |
| Ethicon US, LLC | $15.98 | 2024 | Dermabond |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elshaday Teferi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.